Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
7
self-reported 2–10 band
Founded
2017
9 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
1
Grant · Jul 2025 · US$ 215.9K
Company type
Partnership
self-reported
Legal entity
1 brand → 1 confirmed entity
ANAXIS PHARMA PTY LTD
ABN24618735416
Legal entities
Show as table · Anaxis Pharma: 1 registry entity
| ANAXIS PHARMA PTY LTD | ABN 24618735416 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Anaxis Pharma is an Australian Biotech company developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death. This process, involving both kinases and pseudokinases, is central to and dysregulated in chronic inflammatory disease. Targeting necroptosis fulfils an unmet medical need for patients with diseases including irritable bowel disease, Crohn’s disease, liver fibrosis and reperfusion injury.
As an innovative joint venture between Synthesis Research and the Walter and Eliza Hall Institute of Medical Research, we leverage the extensive expertise and capabilities of the Institute, with the medicinal chemistry experience available to SYNthesis Research. Anaxis Pharma delivers on complex medicinal chemistry campaigns focused on hit-to-lead, lead optimisation and preclinical drug candidate selection. Anaxis has been able to attract funding from major pharma for two of its pre-clinical programs and is now uniquely positioned to rapidly advance their partnered programs to the clinic.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU1G Royal Parade, Parkville; Melbourne, Victoria 3052Primary
Grid intelligence Members
Funding
Rounds1
Round typeGrant · non-equity funding
Amount (USD)215,900
Stage rank1
Investors named1
Since last round6 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2017 to 2026 |
| Grant · 20 Jul 2025 | US$ 215.9K |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Anaxis Pharma?
One Victoria entity on the ABR. ANAXIS PHARMA PTY LTD (ABN 24 618 735 416), high confidence.
How many people work at Anaxis Pharma?
The record holds 7 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Anaxis Pharma have offices?
One address on record, Australia only. Primary: 1G Royal Parade, Parkville, Melbourne, Victoria 3052.
Has Anaxis Pharma raised funding?
One round. Latest 20 July 2025: grant, US$215,900, investor MTPConnect.
Which companies are listed alongside Anaxis Pharma?
19 profiles list Anaxis Pharma as a peer — 93rd percentile in Biotechnology Research. It lists ten peers of its own. SYNthesis Research and Nanomedx list it back.